Detection of Point Mutation in Individual Living Circulating Malignant Cells by Targeting Molecular Beacon Delivery.
Single-cell mutation detection in liquid biopsies reaches new sensitivity without destroying cells, advancing minimally invasive cancer monitoring.
This study introduces a molecular beacon-based system capable of detecting oncogenic point mutations at single-cell resolution in living circulating malignant cells, combining nanotechnology with liquid biopsy principles. The technology enables real-time mutation profiling in CTCs without cell lysis, representing a conceptual advance toward ultra-sensitive, minimally invasive cancer diagnostics.
What the study was
- Study design
- Experimental proof-of-concept
- Population
- Circulating malignant cells from cancer patients and cell lines
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Small (Weinheim an der Bergstrasse, Germany)
Why it surfaced
Single-cell mutation detection in living CTCs is a significant methodological advance for liquid biopsy. Point mutation detection in individual CTCs addresses a major limitation of current cfDNA approaches. Published in Small (Wiley), a high-impact nanomaterials/nanomedicine journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.